Adriamycin resistance modulation induced by lonidamine in human breast cancer cells

G. Zupi, A. Molinari, I. D'Agnano, S. Meschini, D. Del Bufalo, P. Matarrese, A. Candiloro, A. Calcabrini, G. Citro, G. Arancia

Research output: Contribution to journalArticlepeer-review


The effect of Lonidamine (LND), an energolytic chemosensitizing agent, on the MDR (multidrug resistant) phenotype of a human breast cancer cell line (MCF-7) has been studied. The intracellular adriamycin (ADR) accumulation and distribution, the plasma membrane potential and the P170 glycoprotein phosphorylation, have been analysed after LND treatment. The analysis of the subcellular localisation of ADR in both wild type and resistant MCF-7 cells treated with ADR or ADR + LND revealed that LND induced an ADR intracellular redistribution in both cell lines. MCF-7 ADR resistant cells exposed to LND (50 μg/ml) showed a change in the electrical charges distribution across the plasma membrane and a time-dependent reduction of P170 phosphorylation (70% at 24 hr). These effects were associated with a marked increase in intracellular ADR accumulation in resistant cells.

Original languageEnglish
Pages (from-to)2469-2477
Number of pages9
JournalAnticancer Research
Issue number6 B
Publication statusPublished - 1995


  • Adriamycin
  • Lonidamine
  • MCF-7
  • MDR
  • P170

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Adriamycin resistance modulation induced by lonidamine in human breast cancer cells'. Together they form a unique fingerprint.

Cite this